Pulse Biosciences Inc. (NASDAQ:PLSE) stock is trading higher Friday, with session volume surging to about 1.68 million shares, far above the stock’s average daily volume of roughly 183,000.
Pulse Biosciences unveiled significant clinical data from its nPulse Cardiac Catheter first-in-human feasibility study on Friday, February 6.
The company announcement highlighted successful treatment of atrial fibrillation in 150 patients, showcasing rapid procedure times and minimal adverse effects.
Transforming Atrial Fibrillation Treatment
The findings were presented at the Annual AF Symposium 2026 in Boston, emphasizing the nPulse Cardiac Catheter’s potential to advance atrial fibrillation treatment.
The 165-patient study assessed the initial safety and efficacy of the nPulse Cardiac Catheter System.
“These results validate the safety, effectiveness, lesion quality, and speed benefits that clearly differentiate the nPulse Cardiac Catheter Ablation System as a first-in-class system,” said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences.
What Do These Results Mean For Patients?
The data suggest that the nPulse Cardiac Catheter could reduce atrial fibrillation recurrence rates, which typically range from 20-25%.
Pulse Biosciences is preparing to treat additional patients in Europe and the U.S. as it initiates a pivotal IDE study. The company’s proprietary nPulse technology delivers nanosecond pulses of electrical energy to non-thermally clear cells, potentially offering a superior treatment option.
Technical Analysis
Pulse Biosciences is currently showing a strong bullish setup, trading significantly above its short-term moving averages. This positioning suggests a potential breakout, especially as the stock is 38.5% above its 20-day SMA and 39.8% above its 50-day SMA.
The RSI is currently at 46.10, indicating a neutral momentum state. This level suggests that while the stock isn’t overbought, it also hasn’t reached oversold conditions, leaving room for potential upward movement.
MACD is below its signal line, indicating bearish pressure in the short term. This could suggest that traders should be cautious, as it reflects a lack of strong bullish momentum at the moment.
Key support is at $16.50, while resistance sits at $20.00. If Pulse Biosciences breaks through the resistance level, it could signal a continuation of the upward trend, while a drop below support may indicate a reversal.
Looking at the 12-month performance, Pulse Biosciences’ stock is down 9.57%, which highlights the challenges it has faced over the past year. This longer-term trend suggests that traders should remain vigilant and consider the broader context when making decisions.
Currently, the stock is positioned at 57.4% of its 52-week range, indicating it is closer to the high end than the low. This positioning can be a positive sign, but traders should watch for any signs of weakness that could lead to a pullback.
Traders should keep an eye on the resistance level at $20.00 and the support at $16.50 as critical points for potential price action in the near term. The combination of moving averages, RSI, and MACD suggests a complex picture that requires careful monitoring.
PLSE Price Action: Pulse Biosciences shares were up 38.02% at $14.95 at the time of publication on Friday, according to Benzinga Pro data.
Photo by greenbutterfly via Shutterstock
Recent Comments